Condition Directory

Multiple Myeloma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 8, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2319

Shown on this page

Current sort

How Multiple Myeloma studies are organized in the registry

Myeloma listings distinguish newly diagnosed from relapsed/refractory disease in their titles, and precursor conditions — smoldering myeloma and MGUS — are usually registered as separate condition terms. Cell-based and antibody platforms (CAR-T, bispecific antibodies) appear by name in many current titles.

Terms that often appear in related listings

relapsed refractory myeloma smoldering myeloma CAR-T bispecific

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1117–1128 of 2,319 matching trials for Multiple Myeloma.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, chromatography, high performance liquid chromatography, immunoenzyme technique; Genetic · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1975 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Myeloma
Interventions: Not listed
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: No City Provided, New Jersey

Conditions: Multiple Myeloma
Interventions: Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma, Fatigue
Interventions: AYO light glasses (Experimental), AYO light glasses (Comparator); Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 3
States / cities: Hackensack, New Jersey • New York, New York

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Daratumumab, Dexamethasone, Pomalidomide; Biological · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Wichita, Kansas • Rochester, Minnesota • Saint Louis Park, Minnesota + 2 more

Conditions: Lymphoma, Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab (BMS-901608; HuLuc63); Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 63
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more

Conditions: a Diagnosis of MGUS or SMM by IMWG Criteria
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide, bortezomib, thalidomide, melphalan, autologous stem cell transplant; Drug · Procedure
Lead sponsor: Margarida Magalhaes-Silverman; Other
Eligibility: 65 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Carfilzomib, Chemosensitivity Assay, Dexamethasone, Laboratory Biomarker Analysis, Panobinostat; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: lenalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 11
States / cities: Stamford, Connecticut • Basking Ridge, New Jersey • Brooklyn, New York + 6 more

Conditions: Anemia, ASXL1 Gene Mutation, EZH2 Gene Mutation, IDH1 Gene Mutation, IDH2 Gene Mutation, Plasma Cell Myeloma, Primary Myelofibrosis, Recurrent Plasma Cell Myeloma, Secondary Myelofibrosis, Thrombocytopenia
Interventions: Busulfan, Cyclophosphamide, Fludarabine, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis; Drug · Procedure · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Multiple Myeloma
Interventions: PT-112; Drug
Lead sponsor: Promontory Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 7
States / cities: Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 4 more

About this Multiple Myeloma clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Multiple Myeloma clinical trials

How Multiple Myeloma studies are organized in the registry

Filter and sort this condition

Live official records

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

About this Multiple Myeloma clinical trials directory page